ATMP Forum
  • Home
  • Home – English
  • Senza categoria
Select Page

PARTNERSHIP BETWEEN TAKEDA PHARMACEUTICAL AND POSEIDA THERAPEUTICS FOR A NON-VIRAL APPROACH TO GENE THERAPIES

by Admin | Oct 13, 2021 | Senza categoria

https://medcitynews.com/ Takeda Pharmaceutical is collaborating with Poseida Therapeutics in an effort to provide a safer alternative for the development of gene therapies through non-viral technologies. In fact, currently, one of the obstacles in the advancement of...

TAKEDA AND SELECTA BIOSCIENCES: TOGETHER TO DEVELOP GENE THERAPIES FOR PATIENTS WITH LYSOSOMAL STORAGE DISORDERS

by Admin | Oct 8, 2021 | Senza categoria

https://ir.selectabio.com/ Selecta Biosciences announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited to develop next-generation gene therapies for two indications in the field of lysosomal storage diseases....

TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) BY KITE PHARMA RECEIVES FDA APPROVAL. THE FIRST AND ONLY CAR-T FOR ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.

by Admin | Oct 1, 2021 | Senza categoria

https://www.kitepharma.com/ Kite Pharma, a GILEAD company, has announced that the FDA has approved TECARTUS® (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia...

AIFA: UPDATING OF THE KIMRIAH® (TISAGENLECLEUCEL) TECHNICAL-SCIENTIFIC REPORT

by Admin | Sep 20, 2021 | Senza categoria

Aggiornamento del Report tecnico-scientifico AIFA su KYMRIAH AIFA has released the update of the technical-scientific report regarding KIMRIAH® (tisagenlecleucel) by Novartis. KIMRIAH® is indicated for the treatment of paediatric and young adult patients up to and...

ABBVIE ENTERS THE FIELD OF GENE THERAPIES FOR THE TREATMENT OF MACULAR DEGENERATION. PARTNERSHIP WITH REGENXBIO

by Admin | Sep 13, 2021 | Senza categoria

https://news.abbvie.com/ Abbvie e REGENXBIO announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal...
©MA Provider SRL - Via Vincenzo Monti, 3 - 20123 Milano - P.IVA 07135170962 - REA: MI-1938 161 ITALY
Info: info@atmpforum.com - privacy policy | cookie policy